Dr. Reddy's Laboratories Limited (RDY) Q2 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed aspects: stable financial health with strategic R&D investments and promising biosimilar launches, but concerns over competitive pressures and legal challenges. Strong growth in India and emerging markets is positive, but price erosion in the U.S. and unclear guidance on semaglutide pricing impact sentiments. Given these balanced positives and negatives, a neutral stock reaction is expected.
Key Financial Performance
Consolidated Revenue INR 8,805 crores (USD 992 million), a growth of 9.8% year-over-year and 3% sequentially. Growth supported by integration of consumer health care business and double-digit growth in other markets, offset by lower Lenalidomide sales and price erosion in U.S. generics.
EBITDA Margin 26.7%, decreased by 174 basis points year-over-year and flat sequentially. Decline due to lower Lenalidomide sales, price erosion, and one-time VAT provision.
Gross Profit Margin 54.7%, decreased by 492 basis points year-over-year and 223 basis points sequentially. Decline due to lower Lenalidomide sales, price erosion, inventory provisions, and lower operating leverage in PSAI business.
SG&A Spend INR 2,644 crores (USD 298 million), increased by 15% year-over-year and 3% sequentially. Increase driven by investments in acquired NRT consumer healthcare business and branded generics, along with one-time VAT provision and charges for discontinued pipeline products.
R&D Spend INR 620 crores (USD 70 million), declined by 15% year-over-year and flat sequentially. Decline due to reduced development spend on biosimilars as major investments for abatacept were completed.
Profit After Tax INR 1,437 crores (USD 162 million), a growth of 14% year-over-year and flat sequentially. Growth attributed to favorable jurisdictional tax mix and operational performance.
Free Cash Flow INR 1,046 crores (USD 118 million).
Net Cash Surplus INR 2,751 crores (USD 310 million).
North American Generics Revenue USD 373 million, declined by 16% year-over-year and 7% sequentially. Decline due to price erosion in key products, primarily Lenalidomide.
European Business Revenue USD 135 million, grew by 150% year-over-year and 3% sequentially. Growth driven by acquired nicotine replacement therapy portfolio and new product launches, offsetting price erosion.
Emerging Market Revenue INR 1,655 crores, grew by 14% year-over-year and 18% sequentially. Growth driven by new product launches and favorable ForEx.
India Business Revenue INR 1,578 crores, grew by 13% year-over-year and 7% sequentially. Growth driven by new product launches, improved pricing, and higher volumes.
PSAI Business Revenue USD 108 million, grew by 8% year-over-year and 13% sequentially. Growth supported by new filings and operational improvements.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Launch of Tegoprazan and Linaclotide in India: Strengthened gastrointestinal portfolio with the launch of Tegoprazan under the brand name PCAB and Linaclotide under the brand name Colozo.
Semaglutide and abatacept pipeline progress: Advanced key pipeline programs, including semaglutide and abatacept, with regulatory approvals and positive opinions in India and Europe.
COYA 302 IND application: U.S. FDA accepted the IND application for COYA 302, a novel drug for ALS treatment.
Acquisition of Stugeron and related brands: Entered the anti-vertigo segment across 18 markets in APAC and EMEA.
Nicotine Replacement Therapy (NRT) business integration: Successfully integrated 2/3 of the acquired NRT business by value, including Canada, Australia, and key Western European markets.
Emerging markets growth: Revenue grew by 14% year-on-year and 18% sequentially, driven by new product launches and favorable ForEx.
India market growth: Achieved double-digit growth of 13% year-on-year, driven by new product launches and improved pricing.
Cost efficiency initiatives: Enhanced cost efficiencies across operations while pursuing business development activities.
Regulatory inspections and compliance: Completed several inspections across global facilities, addressing observations and maintaining compliance.
Focus on innovation-led portfolio: Strengthened portfolio through strategic collaborations and launches, including semaglutide and denosumab biosimilar.
Sustainability achievements: Retained MSCI ESG Rating of A, improved ESG Risk Rating, and achieved waste management recognition.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
U.S. Generics Business: The U.S. generics business faced product-specific price erosion and lower sales of Lenalidomide, impacting overall revenue growth.
Gross Profit Margin: Gross profit margin decreased by 492 basis points year-over-year and 223 basis points sequentially due to lower Lenalidomide sales, price erosion in U.S. generics, and one-time inventory provisions from discontinued pipeline products.
SG&A Expenses: SG&A expenses increased by 15% year-over-year, driven by investments in acquired businesses and branded generics. This includes a one-time VAT liability provision and charges related to discontinued pipeline products.
R&D Spending: R&D spending declined by 15% year-over-year due to reduced investments in biosimilars, potentially impacting future innovation and pipeline development.
Regulatory Challenges: The U.S. FDA issued Form 483 observations for multiple facilities, including the Bachupally biologics facility and the Mirfield API facility, which could delay product approvals and impact operations.
Price Erosion in Key Markets: Price erosion in select products, particularly in the U.S. and Europe, continues to pressure revenue growth.
Macroeconomic Challenges in Russia: Despite growth, the Russia business faces macroeconomic challenges that could impact future performance.
Pipeline Rationalization: Rationalization of pipeline products due to regulatory uncertainty, limited market opportunities, or competitive intensity may limit future growth opportunities.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects continued revenue growth driven by broad-based growth across businesses, including contributions from the acquired consumer healthcare business and favorable foreign exchange rates. However, growth may be partially offset by lower contributions from Lenalidomide and price erosion in the U.S. generics market.
Product Launches: The company plans to continue its launch momentum in the second half of the fiscal year, with a focus on new products in North America, Europe, and emerging markets. This includes 7 new products in North America, 8 in Europe, and 24 in emerging markets during the quarter.
Pipeline Development: Key pipeline programs, including semaglutide and abatacept, are advancing. The company received regulatory approvals and positive opinions for several products, including semaglutide injection in India and denosumab biosimilar in Europe. The U.S. FDA accepted an IND application for COYA 302 for ALS treatment.
Operational Efficiency: The company is implementing initiatives to enhance cost efficiencies across operations and is pursuing business development activities to support sustainable growth in the coming quarters.
Market Expansion: The company is integrating the acquired nicotine replacement therapy business, with 2/3 of the business already integrated by value. The next phase will include Southern Europe, Israel, and Taiwan.
India Market Growth: The company aims to strengthen its position in the Indian pharmaceutical market, having moved up to the 9th position with a growth rate of 9.4% compared to the market's 7.8% growth. It launched 11 new brands in India during the quarter.
Strategic Collaborations: The company is actively pursuing strategic collaborations and partnerships to enhance its innovation ecosystem, accelerate development timelines, and expand capabilities in emerging therapeutic areas.
Focus on Biosimilars and GLP-1 Molecules: The company is focusing its R&D efforts on biosimilars and GLP-1 molecules, which offer clear differentiation and strong commercial potential.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Should we expect any REVLIMID in the third quarter?
A:Yes, but less than the current quarter. It is likely to be the last quarter or may have some tail into Q4.
Q:How should we think about the U.S. product pipeline given product discontinuations and lack of meaningful large launch approvals?
A:The main focus in the U.S. R&D pipeline will be biosimilars like abatacept and long-acting peptides. The overall pipeline has about 100 products, with around 20 considered complex generics. The company is focusing on products with a good chance of being first to market.
Q:What gives you confidence in getting approvals for sema in Canada or abatacept?
A:For abatacept, the BLA is expected to be submitted by December 2025, with high confidence due to multiple manufacturing sites, including a U.S. CMO. For sema, feedback from Health Canada is expected soon, and the company is confident about selling the product, even if not in Canada.
Q:What is the legal status of semaglutide litigation in India?
A:The company is challenging the patents in India, and the case is currently in the Delhi High Court. A decision is awaited, and the company can produce and export the product but cannot launch in India until patent expiration in March 2026.
Q:What risk mitigation strategies are in place for abatacept manufacturing?
A:The company has a U.S. CMO in addition to its Bachupally, India facility. This mitigates risks related to regulatory challenges, tariffs, and capacity constraints.
Q:What is the update on in-house fill and finish capacity for semaglutide?
A:The in-house fill and finish capacity will not impact launches in the next 12 months. Two cartridge lines in FTO-11 will significantly expand capacity post-approval, potentially reaching up to 50 million units.
Q:What drove the strong growth in the India business this quarter?
A:The growth was driven by execution of strategy, focus on specific therapeutic areas, inorganic moves like brand acquisitions, and licensing of innovative products. GST disruption was managed well.
Q:What is the revenue size of the Stugeron brand acquired from Janssen?
A:The revenue size is INR 100 crore (India and emerging markets combined).
Q:What is the margin outlook beyond REVLIMID?
A:The company maintains its commitment to achieving 25% EBITDA margin by FY '27, despite the decline in REVLIMID. Growth will be driven by base business, cost containment, and key products like sema and abatacept.
Q:How has the U.S. base business performed post-REVLIMID?
A:The base business has seen some decline due to price erosion in about five products, but it is stabilizing. No significant additional erosion is expected in the coming quarters.
Q:What is the market outlook for semaglutide in Canada and other regions?
A:The company expects a competitive market in Canada with multiple players. Approval is being sought in 87 countries, with notable markets including India, Brazil, and Turkey. The company is confident about selling 12 million pens in 2026, with potential growth to 15 million or more in 2027.
Q:Can the company maintain double-digit growth in ex-U.S. markets?
A:Yes, growth is expected to continue, driven by NRT business in Europe, biosimilar launches, innovation in India, and biologics in emerging markets.
Q:What is the status of the Phase III trial for abatacept?
A:The trial is expected to be completed very soon, and the company is on track to file the BLA by December 2025.
Q:What further development is required for the subcutaneous version of abatacept?
A:Additional tests are required for submission, but no new Phase III study is needed.
Q:What is the status of the semaglutide market formation in Canada?
A:The market is expected to be competitive with multiple players. The company is focused on obtaining approval and favorable litigation outcomes in India.
Q:What is the cumulative biologic sales across different markets?
A:Biologic sales are growing, with launches in Europe (e.g., bevacizumab, rituximab) and continued growth in India and emerging markets. Future launches include denosumab and abatacept.
Q:What is the gross margin outlook for the PSAI segment?
A:The gross margin is expected to be in the range of 20%-25%, up from the current 18%.
Q:What is the R&D budget allocation for biosimilars and non-generic business?
A:The R&D budget is about 7% of sales, with a focus on biosimilars like abatacept and innovation through partnerships.
Q:What are the risks to the semaglutide market in Canada?
A:The market may face competition from multiple players and potential pricing pressures. The company anticipates a competitive environment.
Q:What is the investment outlook for NRT and branded markets like India and EM?
A:Investments are sustainable and aligned with market growth. Margins are improving as markets transition from Haleon to in-house management.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer on the expected price erosion levels for semaglutide in Canada, stating they had no clue about the potential erosion percentage.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
APIs biosimilar
Act Income
Act tax
Analytics evening
CFO Member
Conference participation
Consolidated INR
Council evening
Diluted INR
Diwali celebration
Dr Investor
ETR period
Investor Relations
Lenalidomide sale
PBT
USD basis
USD increase
VAT provision
charge
consumer health
contract
crore INR
crore USD
discontinuation product
evening welcome
health care
income INR
increase basis
liability
percentage revenue
product price
rate INR
revenue basis
reversal
RDY Transcript
Dr. Reddy's Laboratories Limited (RDY) Q4 2026 Earnings Call Transcript
Positive5-12
The earnings call summary and Q&A session reveal strong financial performance, product development, and market expansion strategies. Despite some challenges, such as lower gross margins and the wind-down of CAR-T investments, the company's optimistic guidance, new product launches, and market share gains indicate positive sentiment. The focus on emerging markets and sustainability goals further supports a positive outlook. The Q&A insights align with the earnings call, reinforcing the positive sentiment, especially with the expected growth in biosimilars and semaglutide. Therefore, the stock price is likely to experience a positive movement of 2% to 8%.
Dr. Reddy's Laboratories Limited (RDY) Q3 2026 Earnings Call Transcript
Positive1-21
The earnings call highlights strong revenue growth, successful product launches, and strategic collaborations, particularly in the Indian market. Despite a decline in PAT, the company maintains a robust cash position and expects sustainable growth. The Q&A reveals optimism about innovative products and market expansion, though there are some uncertainties in biosimilar timelines. Overall, the positive developments, particularly in India, and optimistic guidance outweigh the negatives, suggesting a positive stock price movement.
Dr. Reddy's Laboratories Limited (RDY) Q2 2026 Earnings Call Transcript
Unknown10-24
The earnings call reveals mixed aspects: stable financial health with strategic R&D investments and promising biosimilar launches, but concerns over competitive pressures and legal challenges. Strong growth in India and emerging markets is positive, but price erosion in the U.S. and unclear guidance on semaglutide pricing impact sentiments. Given these balanced positives and negatives, a neutral stock reaction is expected.
Dr. Reddy's Laboratories Limited (RDY) Q4 2025 Earnings Call Transcript
Unknown5-9
Financial performance is mixed with strong EBITDA growth but declining annual EBITDA margin. Concerns include rising expenses, unclear tariff impacts, and competitive pressures on semaglutide. Positive aspects are stable US price erosion and strong US business growth. Management's lack of clarity on tariffs and severance costs adds uncertainty. Overall, the mixed signals suggest a neutral stock price movement.
RDY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
